Table 3.
The effects of long-term treatment by LA therapy (average yearly reduction) on selected parameters of lipid metabolism, inflammatory biomarkers, and soluble endoglin
| Parameter | HeFH (n = 10) | HeFH (n = 10) | HoFH (n = 4) | HoFH (n = 4) |
|---|---|---|---|---|
| Lipids, mmol/L | Decrease, n (%) | Mean decrease (SD)/year | Decrease, n (%) | Mean decrease (SD)/year |
| TC | 8 (80) | 0.18 (0.08) | 4 (100) | 0.93 (1.2) |
| LDL-C | 6 (60) | 0.18 (0.06) | 2 (50) | 0.37 (0.19) |
| HDL-C | 5 (50) | 0.04 (0.01) | 2 (50) | 0.04 (0.01) |
| apoB | 1 (10) | 0.06 (0) | 0 (0) | – |
| Soluble endoglin, ng/mL | 3 (30) | 0.37 (0.15) | 1 (25) | 0.52 (0) |
| CD40L, pg/mL | 3 (30) | 714 (193) | 2 (50) | 477 (122) |
| hsCRP, mg/L | 0 (0) | – | 3 (75) | 0.62 (0.49) |
| MCP-1, pg/mL | 3 (30) | 27.29 (4.84) | 1 (25) | 15.99 (0) |
| sP-selectin, ng/mL | 4 (40) | 9.92 (6.43) | 0 (0) | – |
Data shows how many patients LA resulted in the change of studied parameters. Moreover, we show an average yearly reduction of levels/biomarkers after LA (where the average is computed over those patients exhibiting a statistically significant reduction)